Editor-in-Chief
Jean-Louis Vincent
Competing interests – guidance for authors
A competing interest exists when your interpretation of data or presentation of information may be influenced by your personal or financial relationship with other people or organizations. Authors should disclose any financial competing interests but also any non-financial competing interests that may cause them embarrassment were they to become public after the publication of the manuscript.
Authors are required to complete a declaration of competing interests. All competing interest that are declared will be listed at the end of published articles. Where the authors do not declare any competing interests, the listing will read: ’The author(s) declare that they have no competing interests’. Please return one copy of this form, which should list all authors’ competing interests.
As the corresponding author you are declaring on behalf of your co-authors and it is your responsibility to consult them before completing the form.
Competing interests form
Financial competing interests
In the past five years have you received reimbursements, fees, funding, or salary from an organization that may in any way gain or lose financially from the publication of this manuscript, either now or in the future? Is such an organization financing this manuscript (including the article-processing charge)? If so, please specify.
This study was performed without external funding. The article-processing charge is to be supported by the research group. Drs. Schöchl and Csambor have received honoraria as speakers from CSL Behring (manufacturer of fibrinogen concentrate and PCC) and Pentapharm GmbH (manufacturer of the ROTEM device). Dr. Solomon has received honoraria as a speaker and research support from Essex Pharma, CSL Behring, and Pentapharm GmbH. Dr. Kozek-Langenecker has received honoraria as a speaker and research support from Astra Zeneca, Baxter (manufacturer of PCC), B.Braun, Biotest, CSL Behring, Dynabyte, Ekomed, Fresenius Kabi, GlaxoSmithKline, Mitsubishi Pharma, NovoNordisk, and Pentapharm GmbH. All other authors have no conflict of interests to disclose.
Do you hold any stocks or shares in an organization that may in any way gain or lose financially from the publication of this manuscript, either now or in the future? If so, please specify.
No.
Do you hold or are you currently applying for any patents relating to the content of the manuscript? Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript? If so, please specify.
No.
Do you have any other financial competing interests? If so, please specify.
No.
Non-financial competing interests
Are there any non-financial competing interests (political, personal, religious, academic, intellectual, commercial or any other) to declare in relation to this manuscript? If so, please specify.
No.
If you are unsure as to whether you, or one your co-authors, has a competing interest please contact the Editorial Office.
Manuscript code: 8462903543160488
Title of article: Goal-directed coagulation management of major trauma patients using ROTEM-guided administration of fibrinogen and prothrombin complex concentrate. Experience of a single level-one trauma centre.
Author(s): Herbert Schöchl, Cristina Solomon, Csilla Jambor, Georg Hofer, Gisela Scharbert, Wolfgang Voelckel, Sybille Kozek-Langenecker
Signature: Cristina Solomon
(typed name will count as signature)
BioMed Central Ltd (Publisher), Floor 6, 236 Gray's Inn Road, London, WC1X 8HL, UK
BioMed Central Ltd is part of Springer Science+Business Media VAT No. GB 823 8263 26 Registered in England and Wales No. 3680030